Little Green Pharma Ltd

Little Green Pharma Ltd has a market capitalization of AUD 26.61 million, with a current market price of AUD 0.087 per share. The company has 305.86 million shares outstanding, with no dilution from potential share issuance as of the latest data. Analysts have assigned a mean price target of AUD 0.18, with a median and high target also at AUD 0.18, indicating a consensus on the stock's potential.

The company's profitability and return metrics are not available in the current dataset, which limits the ability to compare its performance against industry benchmarks. However, the absence of detailed financial metrics suggests that the company may be in an early stage of development or may not have disclosed comprehensive financial results.

Geographically and segment-wise, the company's exposure is not detailed in the available data. This lack of information makes it difficult to assess the concentration of revenue across different regions or product lines. The company's business model likely depends on a few key products or markets, but this is speculative without further data.

In terms of growth, the company's outlook is not quantified in the dataset. Analysts have issued one "buy" recommendation and no "strong buy" or "hold" ratings, suggesting a cautious but not overly optimistic view of the company's near-term prospects. The absence of detailed revenue history or growth projections further limits the ability to assess the company's trajectory.

The company's risk profile includes a low dilution risk, as there is no evidence of potential share issuance or dilution from convertible instruments. However, liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents. This suggests that the company may not have disclosed sufficient financial information to evaluate its short-term liquidity position.

Recent events or filings are not detailed in the dataset, which limits the ability to assess the company's recent performance or strategic direction. The company's financial and operational disclosures appear to be minimal, which may be due to its size or stage of development.

Revenue A$36.8M, +43,7% YoY; Operating income +52,2% YoY.

• ▍Revenue A$36.8M, +43,7% YoY
• ▍Operating income +52,2% YoY
• ▍Net income +140,8% YoY
• ▍Free cash flow +197,0% YoY
• ▍Net margin 9.0%

Revenue A$25.6M, +29,1% YoY; Operating income +25,6% YoY.

• ▍Revenue A$25.6M, +29,1% YoY
• ▍Operating income +25,6% YoY
• ▍Net income +11,4% YoY
• ▍Free cash flow +37,9% YoY
• ▍Net margin -31.8%